. . . . . . . . . "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)" . . . . . . "Children and adolescents (6-17 years)" . . "2021-08-24T15:53:57.790445"^^ . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB" . "bFZGs0c7LGBIG9dBqo1HIEG03MRkRrue798pF+lybU9f9VuCouDPFCGpMLcCtOY415i4CEcZzffP3RU1MxCNdk1lWl2aN7doGS+Tn/DhmzWDesT6wHJ+2ra/sFejnD0StU7BwOV3FzcbUiPYTTqDcpua6sCJvHIb+RHW+oq3fCg=" . . "2021-08-24T15:53:57.790445"^^ . . .